Dupilumab reduced emergency visits, admissions and steroid courses in eosinophilic COPD

Design

Pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

Population

1,874 adults with COPD and blood eosinophils ≥300 cells/µL

Primary outcome

Annualised ED visits or hospital admissions; systemic steroid use

Effect

ED/admission rate ratio 0.62 (0.43 to 0.90); first event HR 0.55 (0.38 to 0.78)

A pooled analysis of the BOREAS and NOTUS phase 3 trials included 1,874 patients aged 40 to 85 with moderate-to-severe COPD and blood eosinophils of 300 cells/µL or more, randomised to dupilumab 300 mg or placebo for 52 weeks.

Dupilumab reduced emergency department visits or hospital admissions by 38% (rate ratio 0.62) and the risk of a first such event by 45% (HR 0.55). Among patients who had exacerbations, systemic corticosteroid use fell by 42% for severe and 28% for moderate exacerbations.

The trials already showed fewer exacerbations; this analysis shows the reduction extends to the events that matter most to health systems and to cumulative steroid exposure. It applies to a specific group with type 2 inflammation already on inhaled therapy, and cost will confine it to a small number of patients in India.

• Check a blood eosinophil count in every COPD patient with exacerbations
• Confirm inhaler technique and optimise triple therapy first
• Consider dupilumab for exacerbating COPD with eosinophils ≥300 cells/µL where accessible
• Record cumulative oral steroid courses as a marker of treatment need

Why it matters

It shows the biologic reduces the costliest exacerbations and steroid burden, not only exacerbation counts.

Don't overread it

This is a pooled secondary analysis of two trials, and ED visits and admissions were not the primary endpoint.

The statistics, in plain English

A rate ratio of 0.62 means 38% fewer events per patient-year. The interval (0.43 to 0.90) is fairly wide because admissions are less common than exacerbations overall. Pooling two similarly designed trials increases the number of events, which improves precision for rarer outcomes.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.